| | | | | | | A beverage giant is surging on strong earnings, an e-commerce firm is sliding after giving weak profit guidance despite its solid holiday sales, and a biotech stock is up 50%+ after trial results on its lead candidate came out positive. Read on to find out more. | | 📲 Want our updates via text message? Get Elite Trade Club's pre-market insights and hottest stocks straight to your cell for 100% free. Click here to sign up. |
|
| |
|
| Technology (Sponsored) | This tech company grew 32,481%... | | No, it's not Nvidia... It's Mode Mobile, 2023’s fastest-growing software company according to Deloitte. | Just as Uber turned vehicles into income-generating assets, Mode is turning smartphones into an easy passive income source, already helping 45M+ users earn $325M+ through simple, everyday use. | They’ve just been granted their stock ticker by the Nasdaq, and you can still invest in their pre-IPO offering at just $0.26/share. | Invest Now | *Mode Mobile recently received their ticker reservation with Nasdaq ($MODE), indicating an intent to IPO in the next 24 months. An intent to IPO is no guarantee that an actual IPO will occur.
*The Deloitte rankings are based on submitted applications and public company database research, with winners selected based on their fiscal-year revenue growth percentage over a three-year period.
*Please read the offering circular and related risks at invest.modemobile.com. | |
|
| | | | What to Watch | Earnings: | DoorDash, Inc. [DASH]: Aftermarket Energy Transfer LP [ET]: Aftermarket Gilead Sciences, Inc. [GILD]: Aftermarket Welltower Inc. REIT [WELL]: Aftermarket | Economic Reports: | NFIB optimism index [Jan]: 6:00 a.m. |
|
| | Food & Beverages | Coca-Cola Shares Rising in Premarket Trading After Strong Q4 Showing | | Coca-Cola [KO] posted strong fourth-quarter results, with revenue rising 6% year-over-year to $11.5 billion, surpassing analyst expectations. | The company’s net income climbed 11% to $2.2 billion, while diluted earnings per share (EPS) increased by 12% to $0.51. | Operating income for the quarter also saw a sharp 19% rise, reaching $2.7 billion. | For the full year 2024, Coca-Cola posted a 3% increase in net operating revenue, totaling $47.1 billion. Despite the revenue growth, diluted EPS for the year remained steady at $2.46. | CEO James Quincey attributed the company’s performance to its ability to navigate shifting market conditions. | "Our all-weather strategy is working, and we continue to demonstrate our ability to lead through dynamic external environments," he said. | Coca-Cola’s shares are up 3.5% in premarket trade, with investors responding positively to the company’s solid financial performance and its ability to drive growth despite economic challenges. |
|
| | Hotels | Marriott’s Q4 Revenue Above Expectations, But 2025 Guidance is Weak | | Marriott International [MAR] projects lower-than-expected profit for 2025, citing weaker performance in its Greater China market. | The company now expects adjusted earnings per share (EPS) to range between $9.82 and $10.19 for the year, falling short of Wall Street’s forecast of $10.65. | Marriott shares are declining by 1.6% in premarket trading. | The hotel operator has faced headwinds in China, where domestic travel demand has softened due to economic uncertainty, job security concerns, and wage pressures. | Revenue per available room (RevPAR) in Greater China declined by 1.8% in the fourth quarter, reflecting a slowdown in consumer spending. | Despite the weaker guidance, Marriott’s fourth-quarter revenue is $6.43 billion, slightly exceeding analyst estimates of $6.38 billion. | While international travel demand remains strong in other regions, the company’s struggles in China highlight the ongoing challenges in the world’s second-largest economy. | Marriott remains focused on expanding its portfolio and optimizing operations, but investors are watching closely to see how the company navigates slower demand in key Asian markets. | The mixed earnings report reflects broader concerns over global travel trends heading into 2025. |
|
| | | | E-Commerce | Shopify Q4 Sales Above Expectations, But Weak Forecast is Causing Shares to Slide | | Shopify [SHOP] reported better-than-expected fourth-quarter sales, but a weaker-than-hoped profit outlook for the first quarter is weighing on investor sentiment. | Despite a 31% revenue jump to $2.81 billion—its fastest growth in six quarters—Shopify’s stock is down 6% in premarket trading today. | The e-commerce giant has been expanding its AI-powered services, rolling out tools such as “Shopify Magic” and the Sidekick AI assistant. | These tools are designed to help merchants with tasks like inventory management, image generation, and customer analytics. | AI features have driven more small- and medium-sized businesses to the platform, boosting gross merchandise volume by 26% to $94.46 billion in the holiday quarter. | However, these advancements have also led to increased costs. | Shopify expects gross profit dollars to grow at a low-twenties percentage rate in Q1, trailing the 24.2% anticipated by analysts. | Operating expenses as a percentage of revenue are projected to rise to 41%-42%, up from 31.5% in the previous quarter. | While the company forecasts mid-twenties percentage growth in Q1 revenue—aligning with analyst expectations for a 24.4% increase—investors remain cautious about its ability to maintain profitability amid rising expenses. |
|
| | Movers and Shakers | | Lipella Pharmaceuticals Inc. [LIPO] - Last Close: $3.05 | Lipella Pharmaceuticals is a clinical-stage biotech company developing therapies for inflammatory and rare diseases. | Its shares are surging 50%+ premarket after the company reported positive safety results for its lead candidate LP-310 in a 24-patient study. | My Take: If LP-310 secures FDA approval, it could be a big moment for Lipella. However, until then this is a clinical stage firm with a high risk profile, and investors should weigh carefully before putting their money here. |
|
|
|
| Firefly Neuroscience, Inc. [AIFF] - Last Close: $3.10 | Firefly Neuroscience is an AI-driven medtech company focused on improving brain health outcomes through its FDA-cleared Brain Network Analytics (BNA™) platform. | Its shares are rising in early trade after announcing its acceptance into NVIDIA’s Connect program, which will grant the company access to cutting-edge AI tools, hardware, and software. | My Take: Acceptance into NVIDIA’s program is a major validation of Firefly’s approach, but its tech is still experimental, so it might be best to adopt a wait and watch strategy here. |
|
|
|
| SelectQuote, Inc. [SLQT] - Last Close: $4.38 | SelectQuote is a technology-driven insurance distribution platform. | Its shares are soaring 33% in premarket trading after securing a $350 million strategic investment from Bain Capital, Morgan Stanley Private Credit, and Newlight Partners. | My Take: Strategic backing from major investors is a huge positive for SLQT but the firm has struggled with profitability in recent quarters, so be cautious while investing here. |
|
|
|
| | | | | | That’s all for today. Thank you for reading. If you have any feedback, please reply to this email. | Best Regards, | — Adam Garcia
Elite Trade Club |
|
| 📧 Like newsletters? Here are some newsletters our readers also enjoy. Explore | | | | Click here to get our daily newsletter straight to your cell for free. | P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP. |
| |
|
|
|
